Lantern Pharma’s LP-284 Study: A Potential Game-Changer in Cancer Treatment?

Lantern Pharma, Inc. ((LTRN)) announced an update on their ongoing clinical study.

Lantern Pharma, Inc. is conducting a Phase 1 clinical study titled ‘A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Intravenously Administered LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors.’ The study aims to assess the safety and tolerability of LP-284, determine the maximum tolerated dose, and establish a recommended Phase 2 dose. Secondary objectives include evaluating the pharmacokinetics and clinical activity of LP-284.

The intervention being tested is LP-284, a small molecule alkylating agent designed to induce tumor cell death through DNA damage. This drug is intended to treat patients with relapsed or refractory lymphomas and advanced solid tumors.

The study follows an interventional design with a single-group assignment. There is no masking, and the primary purpose is treatment. The study is structured in two parts: Phase 1a for dose escalation to find the maximum tolerated dose, and Phase 1b for dose expansion to further evaluate safety and clinical activity.

The study began on November 3, 2023, with an estimated primary completion date in March 2025. The last update was submitted on March 12, 2025. These dates are crucial as they mark the progress and timeline for potential data release and subsequent phases.

This clinical update could influence Lantern Pharma’s stock performance and investor sentiment, as successful results may enhance the company’s market position in oncology treatments. Investors will be keenly watching for outcomes that could differentiate LP-284 from competitors in the cancer treatment landscape.

The study is ongoing, and further details are available on the ClinicalTrials portal.